Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is one of the top gainers this morning after announcing the result of first interim analysis of Phase 3 ‘Succeed Trial’ of Oral Ridaforolimus in metastatic sarcoma… the independent Data Monitoring Committee of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis and has recommended that it continues to full patient enrollment and completion. The safety data. At 8:50 AM EST shares are up close to 16% at $3.03 on over 800,000 shares. Average volume is 2.9 million shares. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment